#EULAR2020 Most innovative! Vaccination with IFNa-kinoid to induce anti-IFNa antibodies to treat SLE (results of phase IIb trial). https://t.co/rM0z23ieQW @RheumNow https://t.co/OYMdDZl6sb

• https://ard.bmj.com/content/79/3/347

#EULAR2020 OP0160 Prospective study of Hopkins Lupus Cohort: HCQ blood levels can predict risk for thrombotic events in SLE. Dr. M Petri advocates this is another reason for monitoring HCQ whole blood levels. Goal HCQ whole blood level should be 1000-1500 ng/mL @rheumnow https://t.co/mM6jsJ2Qmf

#EULAR2020 OP0163 Updated Lupus Nephritis EULAR/ERA-EDTA Recc: 1. T2T:⬇️proteinuria 50%@6 mo,UPCR<700 mg/g@12mo 2. Class III/IV:MMF, Euro-CYP; MMF+CNI 3. goal pred < 7.5 mg/day@6 mo 4.Class IV: MMF, CNI, CTX 5. Maintain w/MMF, AZP 6.🔃renal Bx w/refract. dz @RheumNow https://t.co/tGaSIDG1ji

#EULAR2020 Dr. Kimme Hyrich reviews the EULAR #COVID19 Registry "Most individuals with rheumatic diseases receiving immunosuppressive therapies recover from COVID19" @rheumnow https://t.co/EdVLUMyHhF

#EULAR2020 panel on #COVID19 spec. situatns: 1. German regtry: very few preg rheum pts w/CV19; cases mild. 2. No info how CV19 affects APS 3. Very few ped rheum cases of CV19- cases mild; outcomes sim to gen peds pop 4. Most rheum pts w/CV19 good prognosis @rheumnow https://t.co/LQVdzJKCgu

#eular2020 #op0302 Ianalumab (VAY736) dual action BAFFreceptor inhibitor/B cell depletion meets primary end point in p2b for pSS: EESDAI⬇️1.92 pts over PBO at wk24. Dis not meet 2ry endpoint ESSPRI&FACIT-F. Good side effect profile w/mild inj site reactions mostly @RheumNow https://t.co/9qsfUNho9h

New #therapeutic strategies in #SLE management #EULAR2020 https://t.co/dhvTKd4EGB

Our study shows that HCQ retinopathy virtually never occurs in first 5 yrs, SLE has more risk than other diseases such as RA and chloroquine has a far higher risk of retinal toxicity OP0333 #EULAR2020 @RheumNow @CRASCRRheum @earlyarthritis https://t.co/ZzRy3po4yw

• https://twitter.com/kdao2011/status/1268532437275025409

#EULAR2020 OP0167 Results are finally in!! MMF can be safely w/drawn in quiescent SLE: prospect RCT (nonblinded) 102 pts. MMF tapered over 12 weeks, f/u 60 weeks; no sig diff for flares in pts who stopped MMF vs. maintained; pts who cont MMF had ⬆️ minor infections. @rheumnow https://t.co/bOnuEBLis9